Skip to main content

Table 2 Calculated probabilities of developing radiogenic side effects for the 55-year-old cohort from previous studies [5, 8]

From: Cost-effectiveness analysis of advanced radiotherapy techniques for post-mastectomy breast cancer patients

Side effect Probability (%) Range (%)
IMRT cardiac toxicity 0.95 0.05–2.58
IMRT CL breast cancer 0.04 0.02–0.06
IMRT lung cancer 0.57 0.08–0.84
STD-VMAT cardiac toxicity 0.97 0.05–2.54
STD-VMAT CL breast cancer 0.11 0.06–0.23
STD-VMAT lung cancer 0.63 0.08–0.95
NC-VMAT cardiac toxicity 0.89 0.05–2.34
NC-VMAT CL breast cancer 0.08 0.02–0.20
NC-VMAT lung cancer 0.54 0.07–0.89
MA-VMAT cardiac toxicity 0.89 0.05–2.31
MA-VMAT CL breast cancer 0.09 0.04–0.20
MA-VMAT lung cancer 0.55 0.07–0.92
TOMO cardiac toxicity 0.98 0.07–2.39
TOMO CL breast cancer 0.10 0.06–0.22
TOMO lung cancer 0.72 0.11–1.18
MIXED cardiac toxicity 0.86 0.05–2.22
MIXED CL breast cancer 0.07 0.03–0.15
MIXED lung cancer 0.63 0.08–1.01
IMPT cardiac toxicity 0.40 0.04–0.84
IMPT CL breast cancer 0.003 0.00–0.007
IMPT lung cancer 0.22 0.03–0.60
  1. CL breast contralateral breast
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us

\